What is Pulmatrix?
Pulmatrix is a specialized biopharmaceutical entity focused on the development of advanced inhaled therapies. Its core value proposition centers on the patented iSPERSE technology, an engineered dry powder platform designed to optimize the delivery of medications directly to the lungs. This approach is specifically engineered to improve patient outcomes by enhancing therapeutic efficacy for serious conditions such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA), while simultaneously mitigating the systemic side effects often associated with traditional delivery methods. Beyond respiratory health, the company is exploring the application of its platform to address neurologic disorders, including acute migraine, demonstrating the versatility of its proprietary delivery architecture.
How much funding has Pulmatrix raised?
Pulmatrix has raised a total of $157.3M across 15 funding rounds:
Debt
$20.5M
Share Placement
$10M
Stock Offering
$9.7M
Stock Offering
$15.9M
Stock Offering
$3M
Multiple Rounds
$20.3M
Stock Offering
$8M
Private Equity
$1M
Debt (2013): $20.5M with participation from Undisclosed
Share Placement (2015): $10M led by Polaris Partners, ARCH Ventures, Altitude Life Science Ventures, and 5AM Ventures
Stock Issuance/Offering (2017): $9.7M supported by Undisclosed
Stock Issuance/Offering (2018): $15.9M featuring Undisclosed
Stock Issuance/Offering (2018): $3M backed by Undisclosed
Stock Issuance/Offering (2019): $1.2M with participation from Undisclosed
Stock Issuance/Offering (2019): $2.5M led by Undisclosed
Stock Issuance/Offering (2019): $16.6M supported by Undisclosed
Stock Issuance/Offering (2020): $8M featuring Undisclosed
Private Equity (2026): $1M, investors not publicly disclosed
Key Investors in Pulmatrix
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise and resources to foster innovation.
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies and fund rigorous science.
Novartis Venture Fund
The venture arm of the global pharmaceutical manufacturer Novartis, focusing on research and development of innovative medications and healthcare solutions to improve patient outcomes worldwide.
What's next for Pulmatrix?
With the successful closure of this recent strategic investment, Pulmatrix is well-positioned to transition its lead candidates through critical clinical phases. The company's strategic roadmap likely involves scaling its manufacturing capabilities and expanding its clinical trial footprint to validate the efficacy of its iSPERSE-based treatments in broader patient populations. As the firm moves deeper into its clinical-stage lifecycle, the focus will shift toward regulatory milestones and potential commercialization partnerships. By leveraging its established intellectual property and the continued support of its institutional backers, Pulmatrix aims to solidify its market position as a leader in precision inhaled medicine, ultimately seeking to redefine the standard of care for patients suffering from chronic lung and systemic diseases.
See full Pulmatrix company page
